Ferring Pharmaceuticals, a biopharmaceutical company globally headquartered in Switzerland, plans to invest CHF 30 million ($31 million) in a new biotechnology center at the company’s existing global headquarters and manufacturing site in Saint-Prex, Switzerland.

Ferring plans to invest approximately $31 million over the next three years in the new Ferring Biotech Center, which is expected to incorporate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities.

In addition to the discovery, development, and manufacture of new biologics, the active pharmaceutical ingredient for Ferring’s fertility treatment Rekovelle (follitropin delta) will be manufactured at the new center.

In January 2018, Ferring signed an agreement with Ligand Pharmaceuticals, a San Diego-based biopharmaceutical company, to use Ligand’s OmniAb platform to discover new human monoclonal antibodies and accelerate development for reproductive medicine and women’s health, urology, and gastroenterology.

Source: Ferring Pharmaceuticals